Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Cowen on Intellia Therapeutics (NTLA): 'We continue to view NTLA as a leader in the gene editing space'

August 4, 2022 11:06 AM EDT

Cowen analyst Joseph Thome reiterated an Outperform rating and {REMOVEPT} price target on Intellia Therapeutics (NASDAQ: NTLA)

The analyst comments "NTLA remains on track to present initial data from NTLA-2001 in ATTR-CM and NTLA-2002 in HAE in H2:22. The... More

RBC Capital on Intellia Therapeutics (NTLA) as Shares Like Over 10%: 'Stock Reaction Overdone'

August 4, 2022 10:17 AM EDT

RBC Capital analyst Luca Issi reiterated an Outperform rating and $150.00 price target on Intellia Therapeutics (NASDAQ: NTLA).

The analyst comments "NTLA announced today a new case of possibly drug-related liver enzyme elevation at 1 mg/kg and is backing off the dose going forward from... More

Intellia Therapeutics (NTLA) Misses Q2 EPS by 5c

August 4, 2022 7:55 AM EDT

Intellia Therapeutics (NASDAQ: NTLA) reported Q2 EPS of ($1.33), $0.05 worse than the analyst estimate of ($1.28). Revenue for the quarter came in at $14.03 million versus the consensus estimate of $9.42 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

... More